Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 242

1.

Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma.

Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF.

Neuro Oncol. 2018 Apr 5. doi: 10.1093/neuonc/noy054. [Epub ahead of print]

PMID:
29660005
2.

Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma.

Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD.

Clin Cancer Res. 2018 Jan 15;24(2):295-305. doi: 10.1158/1078-0432.CCR-17-0963. Epub 2017 Oct 26.

PMID:
29074604
3.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.

Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY.

Neuro Oncol. 2018 Jan 22;20(2):259-267. doi: 10.1093/neuonc/nox151.

4.

Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.

Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF.

Neuro Oncol. 2018 Jan 22;20(2):249-258. doi: 10.1093/neuonc/nox154.

5.

Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology committee.

Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, Brandes AA, Reiss M, Goldman S, Fisher MJ, Pollack IF, Prados MD, Wen PY, Chang SM, Dufour C, Zurakowski D, Kortmann RD, Kieran MW.

Neuro Oncol. 2018 Jan 10;20(1):13-23. doi: 10.1093/neuonc/nox087.

PMID:
28449033
6.

A phase 1 trial of intravenous liposomal irinotecan in patients with recurrent high-grade glioma.

Clarke JL, Molinaro AM, Cabrera JR, DeSilva AA, Rabbitt JE, Prey J, Drummond DC, Kim J, Noble C, Fitzgerald JB, Chang SM, Butowski NA, Taylor JW, Park JW, Prados MD.

Cancer Chemother Pharmacol. 2017 Mar;79(3):603-610. doi: 10.1007/s00280-017-3247-3. Epub 2017 Feb 23.

PMID:
28233053
7.

Inhibition of DNA damage repair by the CDK4/6 inhibitor palbociclib delays irradiated intracranial atypical teratoid rhabdoid tumor and glioblastoma xenograft regrowth.

Hashizume R, Zhang A, Mueller S, Prados MD, Lulla RR, Goldman S, Saratsis AM, Mazar AP, Stegh AH, Cheng SY, Horbinski C, Haas-Kogan DA, Sarkaria JN, Waldman T, James CD.

Neuro Oncol. 2016 Nov;18(11):1519-1528. Epub 2016 Jul 1.

8.

Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk.

Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, Hansen HM, Elhauge E, Ojha J, Francis SS, Madsen NR, Bracci PM, Pico AR, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Jenkins RB, Wiemels JL; ENGAGE Consortium Telomere Group, Samani NJ, Wiencke JK, Wrensch MR.

Oncotarget. 2015 Dec 15;6(40):42468-77. doi: 10.18632/oncotarget.6468.

9.

Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience.

Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA.

J Neurooncol. 2016 Jan;126(1):193-200.

10.

Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence.

Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA.

Neurosurgery. 2015 Aug;62 Suppl 1:160-5. doi: 10.1227/NEU.0000000000000801. Review.

11.

Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

Robinson GW, Orr BA, Wu G, Gururangan S, Lin T, Qaddoumi I, Packer RJ, Goldman S, Prados MD, Desjardins A, Chintagumpala M, Takebe N, Kaste SC, Rusch M, Allen SJ, Onar-Thomas A, Stewart CF, Fouladi M, Boyett JM, Gilbertson RJ, Curran T, Ellison DW, Gajjar A.

J Clin Oncol. 2015 Aug 20;33(24):2646-54. doi: 10.1200/JCO.2014.60.1591. Epub 2015 Jul 13.

12.

Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors.

Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O'Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB.

N Engl J Med. 2015 Jun 25;372(26):2499-508. doi: 10.1056/NEJMoa1407279. Epub 2015 Jun 10.

13.

Toward precision medicine in glioblastoma: the promise and the challenges.

Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM.

Neuro Oncol. 2015 Aug;17(8):1051-63. doi: 10.1093/neuonc/nov031. Epub 2015 May 1. Review.

14.

The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.

Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA.

Neurosurgery. 2015 Aug;77(2):248-53; discussion 253. doi: 10.1227/NEU.0000000000000766.

15.

Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD).

Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK.

Neuro Oncol. 2014 Oct;16 Suppl 7:vii36-47. doi: 10.1093/neuonc/nou226.

16.

Familial gliomas: cases in two pairs of brothers.

Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS.

J Neurooncol. 2015 Jan;121(1):135-40. doi: 10.1007/s11060-014-1611-2. Epub 2014 Sep 11.

PMID:
25208478
17.

Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group.

Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY.

Neuro Oncol. 2015 Feb;17(2):180-8. doi: 10.1093/neuonc/nou154. Epub 2014 Aug 26. Review.

18.

Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk.

Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, Pico AR, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, O'Neill BP, Sicotte H, Eckel-Passow JE; ENGAGE Consortium Telomere Group, van der Harst P, Wiencke JK, Samani NJ, Jenkins RB, Wrensch MR.

Nat Genet. 2014 Jul;46(7):731-5. doi: 10.1038/ng.3004. Epub 2014 Jun 8.

19.

Plexiform neurofibromas, trial design, and the definitions of "progression" and "treatment failure".

Prados MD.

Neuro Oncol. 2014 May;16(5):617-8. doi: 10.1093/neuonc/nou050. Epub 2014 Apr 8. No abstract available.

20.

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.

Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA, Corcoran A, Jones DT, Sturm D, Johann P, Tomita T, Goldman S, Nagib M, Bendel A, Goumnerova L, Bowers DC, Leonard JR, Rubin JB, Alden T, Browd S, Geyer JR, Leary S, Jallo G, Cohen K, Gupta N, Prados MD, Carret AS, Ellezam B, Crevier L, Klekner A, Bognar L, Hauser P, Garami M, Myseros J, Dong Z, Siegel PM, Malkin H, Ligon AH, Albrecht S, Pfister SM, Ligon KL, Majewski J, Jabado N, Kieran MW.

Nat Genet. 2014 May;46(5):462-6. doi: 10.1038/ng.2950. Epub 2014 Apr 6.

21.

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma.

Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA.

Neuro Oncol. 2014 Sep;16(9):1255-62. doi: 10.1093/neuonc/nou044. Epub 2014 Mar 26.

22.

"We will know it when we see it;" bevacizumab and glioblastoma.

Prados MD.

Neuro Oncol. 2014 Apr;16(4):469-70. doi: 10.1093/neuonc/nou036. No abstract available.

23.

A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma.

Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD.

Neuro Oncol. 2014 Jul;16(7):984-90.

24.

Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.

Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL.

Neuro Oncol. 2014 Apr;16(4):567-78. doi: 10.1093/neuonc/not247. Epub 2014 Jan 26.

25.

Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial.

Bloch O, Crane CA, Fuks Y, Kaur R, Aghi MK, Berger MS, Butowski NA, Chang SM, Clarke JL, McDermott MW, Prados MD, Sloan AE, Bruce JN, Parsa AT.

Neuro Oncol. 2014 Jan;16(2):274-9. doi: 10.1093/neuonc/not203. Epub 2013 Dec 12.

26.

Targeting Wee1 for the treatment of pediatric high-grade gliomas.

Mueller S, Hashizume R, Yang X, Kolkowitz I, Olow AK, Phillips J, Smirnov I, Tom MW, Prados MD, James CD, Berger MS, Gupta N, Haas-Kogan DA.

Neuro Oncol. 2014 Mar;16(3):352-60. doi: 10.1093/neuonc/not220. Epub 2013 Dec 4.

27.

Genetic variants in telomerase-related genes are associated with an older age at diagnosis in glioma patients: evidence for distinct pathways of gliomagenesis.

Walsh KM, Rice T, Decker PA, Kosel ML, Kollmeyer T, Hansen HM, Zheng S, McCoy LS, Bracci PM, Anderson E, Hsuang G, Wiemels JL, Pico AR, Smirnov I, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, Sicotte H, Eckel-Passow JE, Wiencke JK, Jenkins RB, Wrensch MR.

Neuro Oncol. 2013 Aug;15(8):1041-7. doi: 10.1093/neuonc/not051. Epub 2013 Jun 3.

28.

Challenges with defining response to antitumor agents in pediatric neuro-oncology: a report from the response assessment in pediatric neuro-oncology (RAPNO) working group.

Warren KE, Poussaint TY, Vezina G, Hargrave D, Packer RJ, Goldman S, Wen PY, Pollack IF, Zurakowski D, Kun LE, Prados MD, Rutkowski S, Kieran MW.

Pediatr Blood Cancer. 2013 Sep;60(9):1397-401. doi: 10.1002/pbc.24562. Epub 2013 Apr 26.

PMID:
23625747
29.

Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system.

Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD; Collaborative Ependymoma Research Network.

Brain Pathol. 2013 Sep;23(5):584-94. doi: 10.1111/bpa.12050. Epub 2013 Mar 28.

PMID:
23452038
30.

Improvement of therapeutic compliance in haemodialysis patients with poor phosphorus control and adherence to treatment with binders: COMQUELFOS study.

Dolores Arenas M, Pérez-García R, Bennouna M, Blanco A, Mauricio O, Prados MD, Lerma JL, Luisa Muñiz M, Belén Martín M; Estudio COMQUELFOS.

Nefrologia. 2013;33(2):196-203. doi: 10.3265/Nefrologia.pre2012.Oct.11726. Epub 2013 Jan 6. English, Spanish.

31.

Inherited variant on chromosome 11q23 increases susceptibility to IDH-mutated but not IDH-normal gliomas regardless of grade or histology.

Rice T, Zheng S, Decker PA, Walsh KM, Bracci P, Xiao Y, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Hsuang G, Wiemels JL, Tihan T, Pico AR, Prados MD, Chang SM, Berger MS, Caron A, Fink S, Kollmeyer T, Rynearson A, Voss J, Kosel ML, Fridley BL, Lachance DH, Eckel-Passow JE, Sicotte H, O'Neill BP, Giannini C, Wiencke JK, Jenkins RB, Wrensch MR.

Neuro Oncol. 2013 May;15(5):535-41. doi: 10.1093/neuonc/nos324. Epub 2013 Jan 29.

32.

Comparing routes of delivery for nanoliposomal irinotecan shows superior anti-tumor activity of local administration in treating intracranial glioblastoma xenografts.

Chen PY, Ozawa T, Drummond DC, Kalra A, Fitzgerald JB, Kirpotin DB, Wei KC, Butowski N, Prados MD, Berger MS, Forsayeth JR, Bankiewicz K, James CD.

Neuro Oncol. 2013 Feb;15(2):189-97. doi: 10.1093/neuonc/nos305. Epub 2012 Dec 21.

33.

Gliosarcoma arising from an oligodendroglioma (oligosarcoma).

Hiniker A, Hagenkord JM, Powers MP, Aghi MK, Prados MD, Perry A.

Clin Neuropathol. 2013 May-Jun;32(3):165-70. doi: 10.5414/NP300577.

PMID:
23254140
34.

Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.

Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY.

Neuro Oncol. 2012 Dec;14(12):1511-8. doi: 10.1093/neuonc/nos264. Epub 2012 Oct 24.

35.

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.

Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY.

Clin Cancer Res. 2012 Nov 1;18(21):6032-9. doi: 10.1158/1078-0432.CCR-12-1841. Epub 2012 Aug 24.

36.

A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation.

Jenkins RB, Xiao Y, Sicotte H, Decker PA, Kollmeyer TM, Hansen HM, Kosel ML, Zheng S, Walsh KM, Rice T, Bracci P, McCoy LS, Smirnov I, Patoka JS, Hsuang G, Wiemels JL, Tihan T, Pico AR, Prados MD, Chang SM, Berger MS, Caron AA, Fink SR, Halder C, Rynearson AL, Fridley BL, Buckner JC, O'Neill BP, Giannini C, Lachance DH, Wiencke JK, Eckel-Passow JE, Wrensch MR.

Nat Genet. 2012 Oct;44(10):1122-5. doi: 10.1038/ng.2388. Epub 2012 Aug 26.

37.

Individual patient-specific immunity against high-grade glioma after vaccination with autologous tumor derived peptides bound to the 96 KD chaperone protein.

Crane CA, Han SJ, Ahn B, Oehlke J, Kivett V, Fedoroff A, Butowski N, Chang SM, Clarke J, Berger MS, McDermott MW, Prados MD, Parsa AT.

Clin Cancer Res. 2013 Jan 1;19(1):205-14. doi: 10.1158/1078-0432.CCR-11-3358. Epub 2012 Aug 7.

38.

PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome.

Mueller S, Phillips J, Onar-Thomas A, Romero E, Zheng S, Wiencke JK, McBride SM, Cowdrey C, Prados MD, Weiss WA, Berger MS, Gupta N, Haas-Kogan DA.

Neuro Oncol. 2012 Sep;14(9):1146-52. doi: 10.1093/neuonc/nos140. Epub 2012 Jun 29.

39.

Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors.

Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK.

Cancer Discov. 2012 May;2(5):458-71. doi: 10.1158/2159-8290.CD-11-0284. Epub 2012 Mar 31.

40.

SSBP2 variants are associated with survival in glioblastoma patients.

Xiao Y, Decker PA, Rice T, McCoy LS, Smirnov I, Patoka JS, Hansen HM, Wiemels JL, Tihan T, Prados MD, Chang SM, Berger MS, Kosel ML, Fridley BL, Lachance DH, O'Neill BP, Buckner JC, Thompson RC, Nabors LB, Olson JJ, Brem S, Madden MH, Browning JE, Wiencke JK, Egan KM, Jenkins RB, Wrensch MR.

Clin Cancer Res. 2012 Jun 1;18(11):3154-62. doi: 10.1158/1078-0432.CCR-11-2778. Epub 2012 Apr 3.

41.

Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.

Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1507-18. doi: 10.1007/s00280-012-1854-6. Epub 2012 Mar 7.

42.

Clinical stratification of glioblastoma based on alterations in retinoblastoma tumor suppressor protein (RB1) and association with the proneural subtype.

Goldhoff P, Clarke J, Smirnov I, Berger MS, Prados MD, James CD, Perry A, Phillips JJ.

J Neuropathol Exp Neurol. 2012 Jan;71(1):83-9. doi: 10.1097/NEN.0b013e31823fe8f1.

43.

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS.

Cancer Discov. 2011 Oct;1(5):442-56. doi: 10.1158/2159-8290.CD-11-0102. Epub 2011 Sep 15. Erratum in: Cancer Discov. 2012 Feb;2(2):290-1.

44.

Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS.

J Clin Oncol. 2011 Dec 1;29(34):4482-90. doi: 10.1200/JCO.2010.33.8715. Epub 2011 Oct 24.

45.

Investigation of intravenous delivery of nanoliposomal topotecan for activity against orthotopic glioblastoma xenografts.

Serwer LP, Noble CO, Michaud K, Drummond DC, Kirpotin DB, Ozawa T, Prados MD, Park JW, James CD.

Neuro Oncol. 2011 Dec;13(12):1288-95. doi: 10.1093/neuonc/nor139. Epub 2011 Sep 27.

46.

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.

Butowski N, Chang SM, Lamborn KR, Polley MY, Pieper R, Costello JF, Vandenberg S, Parvataneni R, Nicole A, Sneed PK, Clarke J, Hsieh E, Costa BM, Reis RM, Hristova-Kazmierski M, Nicol SJ, Thornton DE, Prados MD.

Neuro Oncol. 2011 Dec;13(12):1331-8. doi: 10.1093/neuonc/nor130. Epub 2011 Sep 6.

47.

Neurosurgical management and prognosis of patients with glioblastoma that progresses during bevacizumab treatment.

Clark AJ, Lamborn KR, Butowski NA, Chang SM, Prados MD, Clarke JL, McDermott MW, Parsa AT, Berger MS, Aghi MK.

Neurosurgery. 2012 Feb;70(2):361-70. doi: 10.1227/NEU.0b013e3182314f9d.

PMID:
21841523
48.

Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy.

Pejavar S, Polley MY, Rosenberg-Wohl S, Chennupati S, Prados MD, Berger MS, Banerjee A, Gupta N, Haas-Kogan D.

J Neurooncol. 2012 Jan;106(2):367-75. doi: 10.1007/s11060-011-0671-9. Epub 2011 Aug 9.

PMID:
21826561
49.

Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?

Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD; North American Brain Tumor Consortium.

Neuro Oncol. 2011 Oct;13(10):1118-24. doi: 10.1093/neuonc/nor110. Epub 2011 Aug 2.

50.

It is time to include patients with brain tumors in phase I trials in oncology.

Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM.

J Clin Oncol. 2011 Aug 20;29(24):3211-3. doi: 10.1200/JCO.2011.36.6328. Epub 2011 Jul 18. No abstract available.

Supplemental Content

Loading ...
Support Center